The clinical significance of methylation of MAGE-A1 and-A3 promoters and expression of DNA methyltransferase in patients with laryngeal squamous cell carcinoma
American Journal of Otolaryngology - Head and Neck Medicine and Surgery Nov 29, 2019
Liu S, et al. - Given a significant role of abnormal DNA methylation in clinical diagnosis and prognosis of various tumors and catalysis of DNA methylation by DNA methyltransferase (DNMT), researchers examined the methylation levels of MAGE (melanoma-associated antigens)-A1, -A3 in LSCC (laryngeal squamous cell carcinoma) and corresponding normal tissues. They analyzed the expression of DNMTs (DNMT1, DNMT3a and DNMT3b) in LSCC and the relationship between the methylation status of MAGE-A1, -A3. They obtained 106 patients with LSCC from the Department of Otolaryngology, the Fourth Clinical Hospital of Medical University in 2008–2010. They took the corresponding normal tissues from the resected tissues of 106 LSCC patients, about 1 cm away from the tumors. In LSCC tissues, the unmethylation rate of MAGE-A1 was 39.62% and of MAGE-A3 was 46.23%; the expression of DNMTs was 33.02% to 37.74%. They identified a negative correlation of the level of demethylation of MAGE-A1 and MAGE-A3 with DNMTs protein. As per findings, independent prognostic factors for LSCC are MAGE-A1 and MAGE-A3 unmethylation status and DNMT3a expression.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries